CMEF 2026 Successfully Concluded
On April 12, 2026, the four-day 93rd China International Medical Equipment Fair (Spring) (CMEF) successfully concluded at the National Exhibition and Convention Center in Shanghai! Under the theme Innovation Integration · Infinite Leap, this highly influential professional medical device exhibition in China brought together nearly 5,000 enterprises from around the globe and a large number of professional visitors to explore the future of the industry. As a pioneer of local innovation in the life sciences sector, Diagreat made a high-profile appearance with its full range of core products and cutting-edge technologies. We engaged in in-depth exchanges with industry peers worldwide to discuss development opportunities, returning with abundant industry insights and promising cooperation prospects.
Whole-Process Intelligent TDM
Redefining Precision Medication
At this CMEF event, Diagreat integrated three core technologies to build a high-efficiency solution for drug concentration monitoring. Through technological innovation, we broke through the bottlenecks of traditional Therapeutic Drug Monitoring (TDM) and established new industry standards. The fully automated sample pretreatment system enables rapid processing; the TDM testing platform delivers precise data; and the MIPD prediction system provides result interpretation. Working in synergy, the three achieve full-process intelligence from sample handling to result interpretation, eliminating cumbersome operations. This makes drug concentration monitoring faster, more accurate and simpler, providing strong support for precision medication.
Global Linkage, Win-Win Cooperation
At the exhibition, Diagreat attracted strong interest from numerous industry experts, customers and peers with its cutting-edge technologies, including the fully automated chemiluminescence solution for therapeutic drug monitoring, innovative fluorescent immunochromatographic (POCT) product series, biochemical reagent series, and key upstream raw materials. In-depth discussions were held on R&D strategies and practical experience. Diagreat’s independent R&D capabilities and innovative solutions were highly praised, and many parties expressed positive intentions for cooperation.
Moving forward, Diagreat will continue to deepen its presence in precision medicine, committed to bringing more advanced and user-friendly testing solutions to domestic and global markets. We will join hands with partners to advance the development of personalized medicine and contribute local innovative strength to the cause of human health！